One-Year Benefits Sustain Momentum For Kyverna's Autoimmune CAR-T Therapy; Stock Up

Kyverna Therapeutics reported positive one-year data for miv-cel in stiff person syndrome, citing durable clinical responses and a favorable safety profile. Longer-term follow-up in generalized myasthenia gravis also showed positive results, supporting the clinical profile of the company’s cell therapy program. The update is a constructive clinical catalyst for KYTX, though the article provides no quantitative efficacy or safety details.